Date: 2018-10-18
Type of information: Production agreement
Compound: tumor infiltrating lymphocyte (TIL)
Company: Iovance Biotherapeutics (USA - CA) MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism: tumor infiltrating lymphocyte (TIL)
Disease:
Details:
Financial terms:
Latest news: